Clinical Trial Update: Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating front-line Tafasitamab with Rituximab for monomorphic and polymorphic post-transplant lymphoproliferative disorder, currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monomorphic Post-transplant Lymphoproliferative Disorder
• Polymorphic Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• Monjuvi (tafasitamab)
• Rituxan (rituximab)

Snippet

Sponsor: Timothy Voorhees | Conditions: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Status: RECRUITING